Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 29.
doi: 10.1038/s41388-025-03550-6. Online ahead of print.

RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma

Affiliations

RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma

Hexu Han et al. Oncogene. .

Abstract

Programmed death ligand 1 (PD-L1) is a protein expressed in hepatocellular carcinoma (HCC) that drives immune evasion by binding to programmed death receptor 1 (PD-1) on activated T cells. Understanding PD-L1 regulation is essential to understand the immunosuppressive microenvironment for antitumor immunity. We screened ribonucleic acid (RNA)-binding motif proteins (RBMs). RBM30 can enhance PD-L1 expression in HCC cells. In this study, we found that high RBM30 expression in tumor tissues can drive HCC tumor immune evasion and accelerate disease progression via increased PD-L1 transcription. We conducted multiple molecular and high-throughput assays to elucidate the intrinsic molecular mechanisms by which RBM30 upregulates PD-L1 expression in HCC. RBM30 binds to DNA near the transcriptional start site of STAT1 and recruits DOT1L to promote H3K79me3 enrichment, enhancing its accessibility to upregulate STAT1 transcription, consequently activating the PD-L1 transcription. This enhances PD-L1 expression to facilitate immune evasion. These findings reveal the vital role of RBM30 in HCC immune evasion.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The experimental protocol was approved by the Institutional Ethics Review Board of The Affiliated Taizhou People’s Hospital of Nanjing Medical University (2022-008-01). Animal ethical certificates were approved by the Experimental Center of Jiangsu Hanjiang Biotechnology Co., Ltd (HJSW-23050302), and the animals were raised according to animal welfare laws.

Similar articles

References

    1. Endo Y, Sasaki K, Moazzam Z, Woldesenbet S, Yang J, Araujo Lima H, et al. The impact of a liver transplant program on the outcomes of hepatocellular carcinoma. Ann Surg. 2023;278:230–8. - PubMed
    1. Brown Z, Tsilimigras D, Ruff S, Mohseni A, Kamel I, Cloyd J, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–20. - PubMed
    1. He M, Huang Y, Du Z, Lai Z, Ouyang H, Shen J. et al. Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clin Cancer Res. 2023;29:5104–5115. https://doi.org/10.1158/1078-0432.CCR-23-0060 . - PubMed
    1. Zanuso V, Rimassa L, Braconi C. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology. 2025;81:1365–1386. https://doi.org/10.1097/HEP.0000000000000572 . - PubMed
    1. Yu S. Immunotherapy for hepatocellular carcinoma: recent advances and future targets. Pharmacol Ther. 2023;244:108387. - PubMed

LinkOut - more resources